Opinions+ Ashu Singhal and Sajith Wickramasekara STAT Plus: Could billions of dollars in AI funding lead to the same number of new drugs?
Opinions+ Lee A. Fleisher and Matthew A. Fleisher STAT Plus: Use evidence to support early coverage of gene therapy after accelerated approval
Opinions+ Kyle H. Sheetz and Robert M. Wachter STAT Plus: Medical devices makers are trying to take a page from Uber’s playbook
First Opinion Amit Etkin STAT Plus: It’s time to rethink everything about our approach to psychiatric drug development
First Opinion Juliana M. Reed STAT Plus: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira
First Opinion Dan Troy STAT Plus: A California court is setting a dangerous precedent over drug development (or lack thereof) liability
Opinions+ John Whyte STAT Plus: Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit
First Opinion Shirley Leung STAT Plus: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker
Opinions+ Paul Jones STAT Plus: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint
First Opinion Tommy Bramley, Herbert Altmann, and Casper Paardekooper STAT Plus: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients
First Opinion Brian Finrow STAT Plus: Preventive drugs may be the best solution to the antibiotic resistance crisis
First Opinion Vijay Ramakrishnan STAT Plus: How payer-participating trials could help transform clinical research on FDA-approved drugs
First Opinion Leah Christl STAT Plus: The problem with potential changes to the biosimilar regulatory framework
First Opinion Anna Sparrow STAT Plus: One way to create resilient drug supply chains: incentivize predictive models
First Opinion Owen Tripp STAT Plus: How I’m helping companies think through whether they should cover GLP-1s like Ozempic for employees
First Opinion Gloria Coronado and Leslie Bienen STAT Plus: An overlooked way to make participants in clinical trials look more like America
Opinions+ Peter G. Lurie and Beth Ellikidis STAT Plus: Where are the guidelines for the production of animals with intentional genomic alterations?
Opinions+ Dave Greenwald STAT Plus: 3 keys to successful biopharma-academia drug development collaborations
Opinions+ Irfan Khan STAT Plus: Developing new drugs starts with building the next generation of clinical investigators
Opinions+ Christine Swisher and Gabriel Seidman STAT Plus: 4 concrete steps to realize the AI Bill of Rights for clinical decision support software
Opinions+ Patricia Hurter STAT Plus: Continuous manufacturing can help pharma companies save time, money, and more
Opinions+ Ashley Beecy, Steve Miff, and Karandeep Singh STAT Plus: HHS’s proposed rule prohibiting discrimination via algorithm needs strengthening
Opinions+ Meg Richards STAT Plus: The need for regulatory grade evidence: Are you in the stadium or the sandbox?